Brain

1. HOLM RP, Wandall-Holm MF, Magyari M
   Multiple sclerosis in Denmark (1950-2023): mean age, sex distribution, incidence and prevalence.
   Brain. 2024 Jul 20:awae245. doi: 10.1093.
   

   >> Share

   
   
2. TAYLOR BV, Ponsonby AL, Stein M, Lucas R, et al
   Reply: Putative benefits of vitamin D supplements in multiple sclerosis out of reach due to sample size.
   Brain. 2024 Jul 19:awae246. doi: 10.1093.
   

   >> Share

   
   
3. SCHNEIDER-HOHENDORF T, Wunsch C, Falk S, Raposo C, et al
   Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation.
   Brain. 2024 Jul 18:awae244. doi: 10.1093.
   

   >> Share

   
   
4. CORSTEN CEA, Wokke BHA, Smolders J
   Putative benefits of vitamin D supplements in multiple sclerosis out of reach due to sample size.
   Brain. 2024 Jul 16:awae238. doi: 10.1093.
   

   >> Share

   
   

   
   J Neurol

5. MOLENAAR PCG, Noteboom S, van Nederpelt DR, Krijnen EA, et al
   Digital outcome measures are associated with brain atrophy in patients with multiple sclerosis.
   J Neurol. 2024 Jul 15. doi: 10.1007/s00415-024-12516.
   

   >> Share

   
   
6. RAVANO V, Andelova M, Piredda GF, Sommer S, et al
   Microstructural characterization of multiple sclerosis lesion phenotypes using multiparametric longitudinal analysis.
   J Neurol. 2024 Jul 13. doi: 10.1007/s00415-024-12568.
   

   >> Share

   
   

   
   J Neurol Neurosurg Psychiatry

7. GIORDANO A, Clarelli F, Pignolet B, Mascia E, et al
   Vitamin D affects the risk of disease activity in multiple sclerosis.
   J Neurol Neurosurg Psychiatry. 2024 Jul 14:jnnp-2024-334062.
   

   >> Share

   
   
8. MIN YG, Moon Y, Kwon YN, Lee BJ, et al
   Prognostic factors of first-onset optic neuritis based on diagnostic criteria and antibody status: a multicentre analysis of 427 eyes.
   J Neurol Neurosurg Psychiatry. 2024;95:753-760.
   

   >> Share

   
   

   
   J Neurol Sci

9. NIKITINA V, Santi Laurini G, Montanaro N, Motola D, et al
   Safety of fingolimod in patients with relapsing remitting multiple sclerosis: A descriptive analysis of data from the EudraVigilance database.
   J Neurol Sci. 2024;463:123132.
   

   >> Share

   
   

   
   Nat Med

10. MEI F, Fancy SPJ, Shen YA, Niu J, et al
    Author Correction: Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis.
    Nat Med. 2024 Jul 12. doi: 10.1038/s41591-024-03162.
    

    >> Share

    
    

    
    Neurology

11. SASTRE-GARRIGA J, Vidal-Jordana A, Toosy AT, Enzinger C, et al
    Value of Optic Nerve MRI in Multiple Sclerosis Clinical Management: A MAGNIMS Position Paper and Future Perspectives.
    Neurology. 2024;103:e209677.
    

    >> Share

    
    
12. WILLIAMS MJ, Amezcua L, Cohan SL, Cohen JA, et al
    Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses.
    Neurology. 2024;103:e209610.
    

    >> Share

    
    

    
    PLoS One

13. CAMPANIONI S, Veiga C, Prieto-Gonzalez JM, Gonzalez-Novoa JA, et al
    Explainable machine learning on baseline MRI predicts multiple sclerosis trajectory descriptors.
    PLoS One. 2024;19:e0306999.
    

    >> Share

    
    

    
    Rev Neurol

14. CANO-DE-LA-CUERDA R, Marcos-Anton S, Blazquez-Fernandez A, Fernandez-Canas M, et al
    Content, educational value and quality analysis of videos about neurorehabilitation in people with multiple sclerosis on YouTube(R).
    Rev Neurol. 2024;79:77-88.
    

    >> Share

    
    

    
    Rev Neurol (Paris)

15. JOUGLEUX C, Joly H, Brissard H, Lenne B, et al
    French consensus procedure for neuropsychological assessment in multiple sclerosis.
    Rev Neurol (Paris). 2024 Jul 12:S0035-3787(24)00558.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share